# First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

> **NCT05527184** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 256 (actual)

## Conditions studied

- Endometrial Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Cervical Cancer

## Interventions

- **DRUG:** IMGN151

## Key facts

- **NCT ID:** NCT05527184
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-11
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527184, "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05527184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*